Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial

Lancet Diabetes and Endocrinology,The - Tập 7 - Trang 189-199 - 2019
Michael P Whyte1, Thomas O Carpenter2, Gary S Gottesman1, Meng Mao3, Alison Skrinar3, Javier San Martin3, Erik A Imel4
1Shriners Hospital for Children, St Louis, MO, USA
2Yale University School of Medicine, New Haven, CT, USA
3Ultragenyx Pharmaceutical, Novato, CA, USA
4Indiana University School of Medicine, Indianapolis, IN, USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Lancet Diabetes and Endocrinology,The

Tập 7

189-199

Thông tin tác giả